AF 106Alternative Names: AF-106
Latest Information Update: 17 Oct 2016
At a glance
- Originator Afimmune
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 27 Sep 2016 Preclinical trials in Inflammation in Ireland (unspecified route)